1. Home
  2. SPPL vs LNAI Comparison

SPPL vs LNAI Comparison

Compare SPPL & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

N/A

Current Price

$2.02

Market Cap

18.2M

Sector

N/A

ML Signal

N/A

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.18

Market Cap

18.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPPL
LNAI
Founded
2016
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.2M
18.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
SPPL
LNAI
Price
$2.02
$0.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.6K
677.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.15
52 Week High
$7.00
$1.66

Technical Indicators

Market Signals
Indicator
SPPL
LNAI
Relative Strength Index (RSI) 30.06 21.76
Support Level N/A N/A
Resistance Level $3.58 $1.11
Average True Range (ATR) 0.32 0.05
MACD -0.06 -0.01
Stochastic Oscillator 5.07 8.55

Price Performance

Historical Comparison
SPPL
LNAI

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: